Spectrum of CT findings in rupture and impending rupture of abdominal aortic aneurysms

D Rakita, A Newatia, JJ Hines, DN Siegel… - Radiographics, 2007 - pubs.rsna.org
Prompt diagnosis of rupture and impending rupture of abdominal aortic aneurysms is imperative.
The computed tomographic (CT) findings of ruptured abdominal aortic aneurysms are …

Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses

…, F Bullrich, CM Croce, K Rai, J Hines… - Blood, The Journal …, 1998 - ashpublications.org
B-cell chronic lymphocytic leukemia (B-CLL) represents a neoplastic disorder caused primarily
by defective programmed cell death (PCD), as opposed to increased cell proliferation. …

[HTML][HTML] Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

…, J Kolitz, L Elias, L Shepherd, J Hines… - … England Journal of …, 2000 - Mass Medical Soc
Background Fludarabine is an effective treatment for chronic lymphocytic leukemia that does
not respond to initial treatment with chlorambucil. We compared the efficacy of fludarabine …

[PDF][PDF] Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4

…, Y Qian, M Altieri, H Dong, J Wang, K Raina, J Hines… - Chemistry & biology, 2015 - cell.com
BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target
in multiple pathological settings, particularly cancer. While BRD4 inhibitors have shown …

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an …

…, VA Morrison, JE Kolitz, L Shepherd, JD Hines… - Blood, 2005 - ashpublications.org
Fludarabine and rituximab combination therapies in chronic lymphocytic leukemia (CLL)
have yielded promising early results, but no comparative efficacy data relative to standard …

Modular PROTAC design for the degradation of oncogenic BCR‐ABL

…, S Jaime‐Figueroa, E Ko, J Hines… - Angewandte Chemie …, 2016 - Wiley Online Library
Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative
therapeutic strategy with the potential to address many of the challenges currently faced in …

[PDF][PDF] Lessons in PROTAC design from selective degradation with a promiscuous warhead

…, BE Smith, GM Burslem, AD Buhimschi, J Hines… - Cell chemical …, 2018 - cell.com
Inhibiting protein function selectively is a major goal of modern drug discovery. Here, we
report a previously understudied benefit of small molecule proteolysis-targeting chimeras (…

HaloPROTACS: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins

DL Buckley, K Raina, N Darricarrere, J Hines… - ACS chemical …, 2015 - ACS Publications
Small molecule-induced protein degradation is an attractive strategy for the development of
chemical probes. One method for inducing targeted protein degradation involves the use of …

[PDF][PDF] The advantages of targeted protein degradation over inhibition: an RTK case study

…, H Dong, Y Qian, J Wang, AP Crew, J Hines… - Cell chemical …, 2018 - cell.com
Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades
as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the …

[BOOK][B] Iron-age societies: from tribe to state in northern Europe, 500 BC to AD 700

L Hedeager, J Hines - 1992 - ehrafarchaeology.yale.edu
Hedeager's aim in this document is to use archaeology, basically the analysis of the material
from approximately 10,000 graves, hoards, and loose finds, to throw some light upon the …